Effect of apolipoprotein E genotypes on the efficacy of ezetimibe monotherapy in patients with statin induced adverse effects

M. Harangi, I. Seres, I. Balogh, Tamás Köbling, János Harangi, J. Varga, László Márk, G. Paragh

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objective: The aim of this study was to clarify the effect of Apolipopro-tein E (ApoE) polymorphism on the efficacy of cholesterol absorption inhibitor ezetimibe monotherapy on lipid parameters. Methods: 63 hyperlipidemic patients with statin induced adverse effects were involved in the study. We examined the effect of 10 mg/day ezetimibe treatment on lipid levels after 3, 6 and 12 months of treatment in patients on a diet of only different ApoE genotypes. Results: Three months of ezetimibe treatment significantly decreased the total cholesterol (TC) (-10.1%), low-density lipoprotein (LDL-C) (-12.0%) (p <0.001) and triglyceride (Tg) (-8%) levels (p <0.05). After 6 and 12 months of treatment reduction in TC, LDL-C and Tg levels were even more pronounced. The genotype distribution of the patients were 2/2: 4.8%, 2/3: 7.9%, 3/3: 68.3%, 3/4: 19.0%. There were no patients with 2/4 and 4/4 genotypes. In patients with 2/3, 3/3 or 3/4 genotype, the ezetimibe treatment tended to be more effective on TC and LDL-C levels than in the 2/2 group, and the efficacy of ezetimibe on Tg levels were slightly better in 2/2 carriers compared to other patients. Conclusions: The ApoE genotype does not predict the efficacy of ezeti-mibe treatment on serum lipid parameters.

Original languageEnglish
Pages (from-to)746-752
Number of pages7
JournalInternational Journal of Clinical Pharmacology and Therapeutics
Volume51
Issue number9
DOIs
Publication statusPublished - Sep 2013

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Apolipoproteins E
Genotype
Lipids
LDL Cholesterol
Triglycerides
Therapeutics
Anticholesteremic Agents
Ezetimibe
Cholesterol
Diet
Serum

Keywords

  • Apolipopro-tein E genotype
  • Ezetimibe
  • Statin induced adverse effect

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

@article{e80d952a73d54282be1ff6fad3576547,
title = "Effect of apolipoprotein E genotypes on the efficacy of ezetimibe monotherapy in patients with statin induced adverse effects",
abstract = "Objective: The aim of this study was to clarify the effect of Apolipopro-tein E (ApoE) polymorphism on the efficacy of cholesterol absorption inhibitor ezetimibe monotherapy on lipid parameters. Methods: 63 hyperlipidemic patients with statin induced adverse effects were involved in the study. We examined the effect of 10 mg/day ezetimibe treatment on lipid levels after 3, 6 and 12 months of treatment in patients on a diet of only different ApoE genotypes. Results: Three months of ezetimibe treatment significantly decreased the total cholesterol (TC) (-10.1{\%}), low-density lipoprotein (LDL-C) (-12.0{\%}) (p <0.001) and triglyceride (Tg) (-8{\%}) levels (p <0.05). After 6 and 12 months of treatment reduction in TC, LDL-C and Tg levels were even more pronounced. The genotype distribution of the patients were 2/2: 4.8{\%}, 2/3: 7.9{\%}, 3/3: 68.3{\%}, 3/4: 19.0{\%}. There were no patients with 2/4 and 4/4 genotypes. In patients with 2/3, 3/3 or 3/4 genotype, the ezetimibe treatment tended to be more effective on TC and LDL-C levels than in the 2/2 group, and the efficacy of ezetimibe on Tg levels were slightly better in 2/2 carriers compared to other patients. Conclusions: The ApoE genotype does not predict the efficacy of ezeti-mibe treatment on serum lipid parameters.",
keywords = "Apolipopro-tein E genotype, Ezetimibe, Statin induced adverse effect",
author = "M. Harangi and I. Seres and I. Balogh and Tam{\'a}s K{\"o}bling and J{\'a}nos Harangi and J. Varga and L{\'a}szl{\'o} M{\'a}rk and G. Paragh",
year = "2013",
month = "9",
doi = "10.5414/CP201905",
language = "English",
volume = "51",
pages = "746--752",
journal = "International Journal of Clinical Pharmacology and Therapeutics",
issn = "0946-1965",
publisher = "Dustri-Verlag Dr. Karl Feistle",
number = "9",

}

TY - JOUR

T1 - Effect of apolipoprotein E genotypes on the efficacy of ezetimibe monotherapy in patients with statin induced adverse effects

AU - Harangi, M.

AU - Seres, I.

AU - Balogh, I.

AU - Köbling, Tamás

AU - Harangi, János

AU - Varga, J.

AU - Márk, László

AU - Paragh, G.

PY - 2013/9

Y1 - 2013/9

N2 - Objective: The aim of this study was to clarify the effect of Apolipopro-tein E (ApoE) polymorphism on the efficacy of cholesterol absorption inhibitor ezetimibe monotherapy on lipid parameters. Methods: 63 hyperlipidemic patients with statin induced adverse effects were involved in the study. We examined the effect of 10 mg/day ezetimibe treatment on lipid levels after 3, 6 and 12 months of treatment in patients on a diet of only different ApoE genotypes. Results: Three months of ezetimibe treatment significantly decreased the total cholesterol (TC) (-10.1%), low-density lipoprotein (LDL-C) (-12.0%) (p <0.001) and triglyceride (Tg) (-8%) levels (p <0.05). After 6 and 12 months of treatment reduction in TC, LDL-C and Tg levels were even more pronounced. The genotype distribution of the patients were 2/2: 4.8%, 2/3: 7.9%, 3/3: 68.3%, 3/4: 19.0%. There were no patients with 2/4 and 4/4 genotypes. In patients with 2/3, 3/3 or 3/4 genotype, the ezetimibe treatment tended to be more effective on TC and LDL-C levels than in the 2/2 group, and the efficacy of ezetimibe on Tg levels were slightly better in 2/2 carriers compared to other patients. Conclusions: The ApoE genotype does not predict the efficacy of ezeti-mibe treatment on serum lipid parameters.

AB - Objective: The aim of this study was to clarify the effect of Apolipopro-tein E (ApoE) polymorphism on the efficacy of cholesterol absorption inhibitor ezetimibe monotherapy on lipid parameters. Methods: 63 hyperlipidemic patients with statin induced adverse effects were involved in the study. We examined the effect of 10 mg/day ezetimibe treatment on lipid levels after 3, 6 and 12 months of treatment in patients on a diet of only different ApoE genotypes. Results: Three months of ezetimibe treatment significantly decreased the total cholesterol (TC) (-10.1%), low-density lipoprotein (LDL-C) (-12.0%) (p <0.001) and triglyceride (Tg) (-8%) levels (p <0.05). After 6 and 12 months of treatment reduction in TC, LDL-C and Tg levels were even more pronounced. The genotype distribution of the patients were 2/2: 4.8%, 2/3: 7.9%, 3/3: 68.3%, 3/4: 19.0%. There were no patients with 2/4 and 4/4 genotypes. In patients with 2/3, 3/3 or 3/4 genotype, the ezetimibe treatment tended to be more effective on TC and LDL-C levels than in the 2/2 group, and the efficacy of ezetimibe on Tg levels were slightly better in 2/2 carriers compared to other patients. Conclusions: The ApoE genotype does not predict the efficacy of ezeti-mibe treatment on serum lipid parameters.

KW - Apolipopro-tein E genotype

KW - Ezetimibe

KW - Statin induced adverse effect

UR - http://www.scopus.com/inward/record.url?scp=84885047927&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885047927&partnerID=8YFLogxK

U2 - 10.5414/CP201905

DO - 10.5414/CP201905

M3 - Article

C2 - 23815818

AN - SCOPUS:84885047927

VL - 51

SP - 746

EP - 752

JO - International Journal of Clinical Pharmacology and Therapeutics

JF - International Journal of Clinical Pharmacology and Therapeutics

SN - 0946-1965

IS - 9

ER -